Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease

NCT01456325 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01456325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01456325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
January 31, 2016
Enrollment
494 (actual)
Sites
213

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer